US0327973006 - Common Stock
ANAVEX LIFE SCIENCES CORP
NASDAQ:AVXL (10/29/2024, 4:30:00 PM)
After market: 5.715 0 (0%)5.715
-0.07 (-1.12%)
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 40 full-time employees. The company went IPO on 2006-04-13. The firm is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The firm analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.
ANAVEX LIFE SCIENCES CORP
630 5Th Avenue, 20Th Floor
New York City NEW YORK 10019
P: 18446893939
CEO: Christopher Missling
Employees: 40
Website: https://www.anavex.com
Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG...
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical...
AVXL stock results show that Anavex Life Sciences missed analyst estimates for earnings per share the third quarter of 2024.
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the...
Webcast and Conference Call To be Held Tuesday, August 6, 2024, 8:30 am ET...
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address...
Here you can normally see the latest stock twits on AVXL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: